Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Stock Information for Tevogen Bio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tevogen Bio Holdings Inc.

Tevogen.AI Nears Completion of PredicTcell(TM) Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen.AI Reports Advancements in PredicTcell(TM) Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Letter to Shareholders from CEO Dr. Ryan Saadi

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.